ROKIT Healthcare, in cooperation with a Massachusetts-based U.S. hospital, has completed pre-clinical studies for cartilage regeneration using the 3D bioprinting technology and is in the process of clinical studies with patients of age-related osteoarthritis in Egypt.
The pre-clinical study, performed together with the Charles Bragdon group at Massachusetts General Hospital, lasted about six months and followed up with the progress of hyaline cartilage regeneration in beagles.
Existing cartilage repair therapies, based on stem cell injections and seeding and culturing of cells onto alternative membranes, have limitations in treating cartilage which has complex 3D structures and compositions. Combining 3D bioprinting with optimized bioinks composed of minced cartilage and autologous solutions from the patient, ROKIT Healthcare seeks to offer a novel therapy that is founded on providing a stable environment for the recruitment of endogenous stem cells and the differentiation of 3D structurally positioned stem cells into chondrocytes in vivo.
“There has yet to be any truly regenerative method for cartilage repair despite osteoarthritis being one of the top public health burdens in this era of aging populations,” said Seok Hwan You, CEO of ROKIT Healthcare. ”Recently on the news there have been reports of recalls of artificial knee cartilage replacements, including products that have for long comprised the majority of cartilage repair markets. This testifies there are intrinsic limitations of synthetic and allogenic tissue engineering methods, and we need to find autologous alternatives that rely on bioprinting of autologous solutions to the defect site and creation of an endogenous regeneration niche. All of this needs to be done in the safest way that minimizes risk and long-term treatments.”
ROKIT Healthcare has completed applying for domestic and international patents for printing the cartilage regenerative 3D constructs using the MRI/CT scan data of the patient and inserting them back into the patient knee while minimizing the incision. Following the initial rounds of pre-clinical study in the U.S. and clinical study in Egypt, the clinical studies are planned to continue in Korea and Singapore.
Subscribe to Our Email Newsletter
Stay up-to-date on all the latest news from the 3D printing industry and receive information and offers from third party vendors.
You May Also Like
AI-driven Software is Unleashing Growth in Additive Manufacturing – AMS Speaker Spotlight
Additive manufacturing has been gradually gaining ground, but the road to widespread mass customization, on-demand and serial production has been bumpy. Manufacturers eager to embrace this technology are held back...
The Fight for Clean Data in Additive Manufacturing – AMS Speaker Spotlight
Dirty data costs the additive industry millions of dollars a year. Material parameter development, operational mistakes, or part failure could all be avoided if reliable, detailed and comprehensive data about...
New Mitsubishi Electric Automation Software Simulates Production Lines for 3D Printing
Mitsubishi Electric Automation, a U.S. subsidiary of the Japanese multinational, has announced the release of MELSOFT Gemini 3D Simulator Software. MELSOFT Gemini 3D is a digital platform designed for simulating...
AME-3D Taps AMFG Automation Software to Strengthen 3D Printing & Vacuum Casting
According to SmarTech Analysis in its “Opportunities in Additive Manufacturing Software Markets 2023” report, this market is expected to grow faster than previous projections showed, as it’s “evolving at a...